The genetic testing company Genome ID has announced it has identified a cluster of genes that may be responsible for autoimmune disease.
The company says it hopes to begin clinical trials of its genetic testing program by the end of 2019.
Genome IDs is a division of Sanofi Pasteur, a global pharmaceutical company.
The news comes amid an increasing number of new autoimmune diseases, which have been linked to a surge in genetic testing.
In the last year alone, the number of autoimmune diseases has nearly doubled, from 10,000 in 2016 to over 27,000 today.
The surge in autoimmune diseases is linked to genetic changes in the human genome that have been identified in an increasing percentage of people.
According to the National Institutes of Health, more than 10,700 people worldwide have some form of autoimmune disease, up from just 2,300 in 2016.
Many of these conditions are associated with autoimmune thyroid disease and multiple sclerosis.
The number of people with autoimmune disorders has doubled in the past decade.
Researchers say they have identified dozens of genes in people who have autoimmune disorders that are linked to autoimmune disease and that these genes could help diagnose and treat these conditions.
“There are a lot of people who do not have a condition,” said GenomeID CEO Andrew J. Lebovitz.
“Some of those people don’t even have any symptoms, and others do, but some of those have a lot more genetic variants.”
People with autoimmune conditions, including Type 1 diabetes, type 2 diabetes, and multiple myeloma, can have abnormal cells called autoantibodies that attack the body’s immune system.
Autoantibody-producing cells can be found in the immune system in the bone marrow and bone marrow transplant recipients.
“People with autoimmune diseases can have autoimmune antibodies, which can trigger autoimmune diseases,” said Leborgitz.
Researchers are still studying how the immune systems of people living with autoimmune disease respond to the genetic tests, but Leborbitz said they have begun to identify genes that are associated to autoimmune diseases.
“It is important to note that this is an association, not a causation,” Leborgantsi said.
“We are only finding these genes in a small subset of people.”
Lebovais said he thinks genetic testing could help treat a range of autoimmune conditions.
He also said it is a very exciting time for genetic testing and for research in genetic disease research.
“I think we will continue to see a big increase in genetic information and the research in genetics,” he said.
Genomic testing companies have been developing tests for autoimmune diseases since the 1980s, and researchers say the industry is rapidly growing.
Genomics is currently used by over 200 million people around the world.
In addition to testing for conditions such as diabetes, autoimmune thyroid, multiple myelloma, and Type 1 diabetic, genetic testing companies are developing tests to diagnose other genetic disorders, such as Huntington’s disease and Down syndrome.
The National Institutes for Health is a private nonprofit organization, funded by taxpayers, that promotes biomedical research and discovery.
Its main mission is to advance health worldwide through the discovery, development, and application of biomedical knowledge.